Two pharmaceutical companies (Avidity and Dyne Therapeutics) are exploiting this high TfR1 expression through the conjugation of DM1 small interfering RNA (siRNA) [84] targeting DMPK transcripts to TfR1 targeting antibodies or antibody fragments. Here, DMPK is linked to myotonic dystrophy type 1.